iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
iBio (NASDAQ:IBIO) reported its fiscal year 2025 results and corporate updates, highlighting significant progress in its cardiometabolic and obesity pipeline. The company's lead candidates include IBIO-610, an activin E-targeting antibody showing 26% fat mass reduction without lean mass loss, and IBIO-600, a long-acting anti-myostatin antibody demonstrating extended half-life and dose-dependent muscle growth.
Financial highlights include revenue of $0.4M (up $0.2M YoY), R&D expenses of $8.3M (up $3.1M), and G&A expenses of $10.7M (down $1.0M). The company strengthened its position through a $50M public offering with potential for additional $50M from warrant exercises. iBio successfully transferred to Nasdaq trading and expanded its leadership team with industry veterans.
iBio (NASDAQ:IBIO) ha presentato i risultati fiscali per l'anno 2025 e aggiornamenti aziendali, sottolineando progressi significativi nella pipeline per cardiometabolismo e obesità. I candidati principali includono IBIO-610, un anticorpo mirato ad activina E che ha mostrato una riduzione della massa grassa del 26% senza perdita di massa magra, e IBIO-600, un anticorpo anti-miostatina a lunga durata d'azione che dimostra emivita prolungata e crescita muscolare dipendente dalla dose.
I punti finanziari salienti comprendono ricavi di 0,4 M$ (in aumento di 0,2 M$ su base annua), spese di R&S per 8,3 M$ (in aumento di 3,1 M$) e spese G&A per 10,7 M$ (in diminuzione di 1,0 M$). L'azienda ha rafforzato la sua posizione tramite un offerta pubblica da 50 M$ con potenziale ulteriore di 50 M$ dagli esercizi dei warrant. iBio è passata con successo alla quotazione sul Nasdaq e ha ampliato il team dirigenziale con figure esperte del settore.
iBio (NASDAQ:IBIO) presentó sus resultados fiscales del año 2025 y actualizaciones corporativas, destacando avances significativos en su cartera para cardiometabolismo y obesidad. Los candidatos principales incluyen IBIO-610, un anticuerpo dirigido a la activina E que mostró una reducción del 26% en masa grasa sin pérdida de masa magra, y IBIO-600, un anticuerpo anti-miostatina de larga acción que demuestra vida media prolongada y crecimiento muscular dependiente de la dosis.
Los aspectos financieros incluyen ingresos de 0,4 M$ (un aumento de 0,2 M$ interanual), gastos de I+D de 8,3 M$ (un aumento de 3,1 M$) y gastos G&A de 10,7 M$ (una disminución de 1,0 M$). La compañía reforzó su posición mediante una oferta pública de 50 M$ con potencial adicional de 50 M$ por el ejercicio de warrants. iBio logró la transferencia para cotizar en Nasdaq y amplió su equipo directivo con veteranos del sector.
iBio (NASDAQ:IBIO)는 2025 회계연도 실적 및 회사 업데이트를 발표하며 심혈관·대사 및 비만 파이프라인에서 중요한 진전을 강조했습니다. 주요 후보물질로는 activin E를 표적하는 IBIO-610이 있으며, 이는 제지방 손실 없이 지방량을 26% 감소시켰고, 장기간 작용하는 항-마이오스타틴 항체인 IBIO-600은 반감기가 연장되고 용량 의존적 근육 증가를 보였습니다.
재무 주요 사항으로는 매출 0.4M$(전년 대비 0.2M$ 증가), 연구개발비 8.3M$(3.1M$ 증가), 일반관리비 10.7M$(1.0M$ 감소)가 포함됩니다. 회사는 50M$ 공모를 통해 재무적 위치를 강화했으며, 워런트 행사로 추가 50M$ 확보 가능성이 있습니다. iBio는 Nasdaq로의 이전 상장을 성공적으로 마쳤고 업계 베테랑들을 영입해 경영진을 확충했습니다.
iBio (NASDAQ:IBIO) a publié ses résultats de l'exercice 2025 et des informations d'entreprise, mettant en avant des progrès significatifs dans sa branche cardiométabolique et anti-obésité. Les candidats principaux comprennent IBIO-610, un anticorps ciblant l'activine E ayant montré une réduction de 26 % de la masse grasse sans perte de masse maigre, et IBIO-600, un anticorps anti-myostatine à longue durée d'action démontrant une demi-vie prolongée et une augmentation musculaire dépendante de la dose.
Les points financiers incluent un chiffre d'affaires de 0,4 M$ (en hausse de 0,2 M$ sur un an), des dépenses R&D de 8,3 M$ (en hausse de 3,1 M$) et des frais G&A de 10,7 M$ (en baisse de 1,0 M$). La société a renforcé sa position via une offre publique de 50 M$ avec un potentiel additionnel de 50 M$ lié à l'exercice de bons de souscription. iBio a réussi son transfert de cotation vers le Nasdaq et a étoffé son équipe de direction avec des vétérans du secteur.
iBio (NASDAQ:IBIO) veröffentlichte seine Ergebnisse für das Geschäftsjahr 2025 und Unternehmensupdates und hob erhebliche Fortschritte in seiner kardiometabolischen und Adipositas-Pipeline hervor. Zu den führenden Kandidaten zählen IBIO-610, ein auf Activin E gerichteter Antikörper, der eine Reduktion der Fettmasse um 26% ohne Verlust der fettfreien Masse zeigte, und IBIO-600, ein langwirksamer Anti-Myostatin-Antikörper mit verlängerter Halbwertszeit und dosisabhängigem Muskelzuwachs.
Finanzielle Highlights umfassen Umsatz von 0,4 Mio. $ (plus 0,2 Mio. $ im Jahresvergleich), F&E-Aufwendungen von 8,3 Mio. $ (plus 3,1 Mio. $) und Verwaltungsaufwendungen von 10,7 Mio. $ (minus 1,0 Mio. $). Das Unternehmen stärkte seine Position durch ein öffentliches Angebot von 50 Mio. $ mit der Möglichkeit zusätzlicher 50 Mio. $ durch Optionsausübung. iBio hat erfolgreich auf den Nasdaq gewechselt und sein Führungsteam mit Branchenveteranen erweitert.
- None.
- R&D expenses increased significantly by $3.1M year-over-year
- Low revenue base of only $0.4M for the entire fiscal year
- Cash position of $8.8M as of June 30, 2025, indicating potential need for additional funding
- All programs still in preclinical stage, indicating long pathway to commercialization
Insights
iBio advances obesity/cardiometabolic pipeline with promising preclinical data while strengthening finances through $50M offering and Nasdaq uplisting.
iBio's fiscal 2025 results reflect a company strategically pivoting toward high-value cardiometabolic and obesity therapeutics. The company has made significant strides with two key preclinical candidates: IBIO-610, an activin E-targeting antibody showing
The financial position has been substantially reinforced through multiple funding initiatives, including a
The company's strategic expansion into obesity represents a timely market positioning, as this therapeutic area has seen explosive growth following the success of GLP-1 agonists. iBio's differentiated approach targeting activin E and myostatin pathways could potentially address key limitations of current obesity treatments - particularly muscle preservation during weight loss. The preliminary data showing fat-selective weight loss with IBIO-610 is particularly noteworthy as it addresses a major clinical need in obesity management.
The collaboration with AstralBio has been productive, yielding all targeted discoveries plus an additional fifth target, along with an amylin receptor antibody showing promising preclinical results. The Nasdaq uplisting and board/management additions further strengthen the company's foundation as it transitions from early research toward clinical development.
iBio strengthened its financial position with $50M offering while advancing promising obesity assets despite increased R&D burn.
iBio's financial results reveal a company intensifying its R&D investment while successfully accessing capital markets to fund its ambitions. R&D expenses increased
The company's cash position of
Revenue generation remains minimal at
The addition of experienced board members with capital markets expertise (David Arkowitz) and the hiring of a business development executive (Kristi Sarno) signals preparation for potential partnerships that could bring non-dilutive funding. The company's strategic focus on obesity positions it in a high-growth therapeutic area with significant partnership potential, though investors should recognize substantial R&D investment will be required before reaching potential commercialization.
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June 30, 2025, and provided a corporate update on its progress.
“This fiscal year has been transformative for iBio as we advanced both our pipeline and corporate strategy,” said Martin Brenner, Ph.D., DVM, Chief Executive Officer and Chief Scientific Officer of iBio. “We began building a differentiated preclinical portfolio in cardiometabolic diseases and obesity, highlighted by IBIO-610, an activin E-targeting antibody with compelling preclinical data supporting high-quality fat loss with muscle preservation, and IBIO-600, our long-acting anti-myostatin antibody. In parallel, we unveiled an additional innovative program, a bispecific antibody against myostatin and activin A, further expanding our next-generation antibody pipeline. Under our collaboration with AstralBio, we discovered a novel amylin receptor antibody. On the corporate side, our successful transfer of the listing of our common stock to Nasdaq, strengthened balance sheet, and the addition of successful industry leaders to our Board and management team have positioned iBio for long-term growth. And we are grateful our science was recently recognized by life sciences investors who participated in our recently closed offering to help us advance our innovative technologies. We remain committed to delivering transformative therapies to patients while driving sustainable value for our shareholders.”
Progress on Cardiometabolic and Obesity Pre-Clinical Pipeline:
- Identified all four targets under the original multi-target discovery collaboration entered with AstralBio, Inc. (“AstralBio”) in April 2024, focused on genetically validated pathways in obesity and cardiometabolic disease, and amended the collaboration agreement in April 2025 to add a fifth target.
- In-licensed IBIO-600 and IBIO-610 from AstralBio, securing full development and commercialization rights to two of the company’s most advanced assets.
- Progressed IBIO-600, iBio’s differentiated long-acting anti-myostatin antibody designed for subcutaneous administration, through a non-GLP non-human primate (NHP) pharmacokinetics (PK) study whose data demonstrated extended half-life and dose-dependent muscle growth.
- Achieved development candidate nomination of IBIO-610, an activin E-targeting antibody, based on strong preclinical data from a 4-week study in diet-induced obese mice demonstrating a
26% reduction in fat mass and no measurable loss of lean mass. These findings demonstrate the potential of IBIO-610 for fat-selective weight loss. - iBio initiated an NHP study for IBIO-610 to evaluate pharmacokinetics and early signs of efficacy in obese and elderly NHPs, including its impact on fat and body composition.
- Initiated a program leveraging iBio’s Machine-Learning Antibody Engine to develop a bispecific antibody targeting myostatin and activin A, and aimed at weight loss promotion, muscle preservation, and weight regain prevention.
- As part of iBio’s collaboration with AstralBio, it unveiled and demonstrated in vivo proof-of-concept for an amylin receptor antibody program with potential to deliver quality weight loss, favorable gastrointestinal tolerability, and lean mass preservation. Studies in a mouse model of obesity demonstrated reduced acute food intake by
60% (p<0.05), comparable to the reduction in food intake from a clinically advanced dual amylin and calcitonin receptor agonist (DACRA) peptide (67% ).
Corporate Developments:
- Began trading on the Nasdaq Stock Market under the ticker symbol “IBIO,” marking a significant corporate milestone and enhancing visibility, improving trading liquidity, and aligning with the company’s strategy to attract long-term institutional investors.
- Raised
$6.2 million in gross proceeds through a warrant inducement transaction with institutional investors, strengthening the company’s balance sheet and providing additional working capital to support advancements in its pipeline. - Recently completed a
$50 million underwritten public offering of pre-funded warrants and common warrants, with potential for an additional$50 million in gross proceeds upon full exercise of the common warrants, for total potential gross proceeds of up to$100 million . - Expanded the Board with biotech industry veterans, David Arkowitz and António Parada, who bring deep sector experience and proven leadership in capital markets and antibody discovery and development.
- Bolstered the executive team with the hiring of Kristi Sarno, Senior Vice President of Business Development, to lead partnering efforts, drive pipeline growth, and accelerate external innovation.
“In fiscal year 2025, we combined disciplined expense management with valuable funding initiatives to advance research and development of our obesity and cardiometabolic disease pipeline,” said Felipe Duran, Chief Financial Officer of iBio. “We secured non-dilutive funding through collaboration revenue and a warrant inducement transaction, allowing us to enter fiscal year 2026 well-positioned to execute on our growth strategy and support development of our clinical drug candidates IBIO-600 and IBIO-610.”
Financial Results:
Revenues for the fiscal year ended June 30, 2025, were approximately
Research and Development (“R&D”) expenses for the fiscal year ended June 30, 2025, and June 30, 2024, were
General and Administrative expenses for the fiscal year ended June 30, 2025, and June 30, 2024, were approximately
iBio held cash, cash equivalents and restricted cash of
About iBio, Inc.
iBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit www.ibioinc.com or follow us on LinkedIn.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding iBio’s ability to build a differentiated preclinical portfolio in cardiometabolic diseases and obesity; the potential of IBIO-610, an activin E-targeting antibody, to support high-quality fat loss with muscle preservation; the addition of successful industry leaders to the company’s Board and management team positioning iBio for long-term growth; iBio’s ability to drive sustainable value for its shareholders; iBio’s Machine-Learning Antibody Engine program successfully developing a bispecific antibody targeting myostatin and activin A, aimed at weight loss promotion, muscle preservation, and weight regain prevention; the ability of iBio’s in vivo proof-of-concept for an amylin receptor antibody program to deliver quality weight loss, favorable gastrointestinal tolerability, and lean mass preservation; the
Contact:
iBio, Inc.
Investor Relations
ir@ibioinc.com
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604
| iBio, Inc. and Subsidiaries Consolidated Statements of Operations (In Thousands, except per share amounts) | ||||||||
| Years Ended | ||||||||
| June 30, | ||||||||
| 2025 | 2024 | |||||||
| Revenue | $ | 400 | $ | 225 | ||||
| Operating expenses: | ||||||||
| Research and development | 8,312 | 5,185 | ||||||
| General and administrative | 10,690 | 11,674 | ||||||
| Total operating expenses | 19,002 | 16,859 | ||||||
| Operating loss | (18,602 | ) | (16,634 | ) | ||||
| Other income (expense): | ||||||||
| Interest expense | (212 | ) | (172 | ) | ||||
| Interest income | 437 | 363 | ||||||
| Gain on sale of intellectual property | — | 1,000 | ||||||
| Total other income | 225 | 1,191 | ||||||
| Net loss from continuing operations | (18,377 | ) | (15,443 | ) | ||||
| Loss from discontinued operations | — | (9,464 | ) | |||||
| Loss | $ | (18,377 | ) | $ | (24,907 | ) | ||
| Loss per common share - basic and diluted - continuing operations | $ | (1.75 | ) | $ | (4.03 | ) | ||
| Loss per common share - basic and diluted - discontinued operations | $ | — | $ | (2.47 | ) | |||
| Loss per common share - basic and diluted - total | $ | (1.75 | ) | $ | (6.50 | ) | ||
| Weighted-average common shares outstanding - basic and diluted | 10,499 | 3,831 | ||||||
| Share and per share data have been adjusted for June 30, 2024 presented to reflect the one-for-twenty (1:20) reverse stock split effective November 29, 2023. | ||||||||
| iBio, Inc. and Subsidiaries Consolidated Balance Sheets (In Thousands, except share and per share amounts) | ||||||||
| June 30, | June 30, | |||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 8,582 | $ | 14,210 | ||||
| Subscription receivable | 105 | — | ||||||
| Promissory note receivable and accrued interest | — | 713 | ||||||
| Prepaid expenses and other current assets | 1,034 | 749 | ||||||
| Total Current Assets | 9,721 | 15,672 | ||||||
| Restricted cash | 210 | 215 | ||||||
| Promissory note receivable | 1,098 | 1,081 | ||||||
| Finance lease right-of-use assets, net of accumulated amortization | 68 | 339 | ||||||
| Operating lease right-of-use asset | 2,051 | 2,401 | ||||||
| Fixed assets, net of accumulated depreciation | 3,163 | 3,632 | ||||||
| Intangible assets, net of accumulated amortization | 6,848 | 5,368 | ||||||
| Security deposits | 26 | 26 | ||||||
| Total Assets | $ | 23,185 | $ | 28,734 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,188 | $ | 358 | ||||
| Accrued expenses | 1,345 | 2,028 | ||||||
| Finance lease obligations - current portion | 53 | 299 | ||||||
| Operating lease obligation - current portion | 490 | 436 | ||||||
| Equipment financing payable - current portion | 64 | 178 | ||||||
| Term promissory note - current portion | 766 | 218 | ||||||
| Insurance premium financing payable | — | 123 | ||||||
| Contract liabilities | 1,200 | 200 | ||||||
| Total Current Liabilities | 6,106 | 3,840 | ||||||
| Finance lease obligations - net of current portion | — | 53 | ||||||
| Operating lease obligation - net of current portion | 2,199 | 2,688 | ||||||
| Equipment financing payable - net of current portion | — | 63 | ||||||
| Term promissory note - net of current portion | — | 766 | ||||||
| Total Liabilities | 8,305 | 7,410 | ||||||
| Stockholders' Equity | ||||||||
| Series 2022 Convertible Preferred Stock - | — | — | ||||||
| Common Stock - | 19 | 9 | ||||||
| Additional paid-in capital | 347,085 | 335,162 | ||||||
| Accumulated deficit | (332,224 | ) | (313,847 | ) | ||||
| Total Stockholders’ Equity | 14,880 | 21,324 | ||||||
| Total Liabilities and Stockholders' Equity | $ | 23,185 | $ | 28,734 | ||||
| Share and per share data have been adjusted for June 30, 2024 presented to reflect the one-for-twenty (1:20) reverse stock split effective November 29, 2023. | ||||||||
FAQ
What were iBio's (IBIO) key financial results for fiscal year 2025?
What are the main drug candidates in iBio's pipeline?
How much funding did iBio raise in its 2025 public offering?
What were the preclinical results for IBIO-610?
How did iBio strengthen its corporate leadership in 2025?
